Óscar Muñoz Aznar
Técnico
Research group
Professional network profiles
Last Publications
- Castillo-Ecija H, Pascual-Pastó G, Pérez-Jaume S, Resa-Pares C, Vilà-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farres M, Muñoz-Aznar O, Salvador-Marcos N, Cuadrado-Vilanova M, Gene-Olaciregui N, Balaguer-Lluna L, Burgueño V, Vicario FJ, Manzanares-Quintela A, Castañeda-Heredia A, Santa-María López V, Cruz-Martínez O, Celis-Passini V, Morales-La Madrid A, Garraus-Oneca M, Gorostegui M, Vancells M, Carrasco-Torrents R, Krauel L, Torner-Rubies F, Suñol M, Lavarino C, Mora J and Montero-Carcaboso A Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas. JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 7(4): 338-349.
- Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz O, Muñoz JP, Ignacio Barber Martínez de la Torre and Suñol M Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers . 13(6): .
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.